Swiss Clinical Trial Organisation (SCTO) Market Research Report

Background

Overview

The Swiss Clinical Trial Organisation (SCTO) is a national research infrastructure and academic reference institution dedicated to high-quality, patient-oriented clinical research in Switzerland. Established in 2009 through a joint initiative by the Swiss National Science Foundation (SNSF) and the Swiss Academy of Medical Sciences (SAMS), the SCTO was designated a research infrastructure of national importance in 2017. It is funded by the State Secretariat for Education, Research and Innovation (SERI) and the SNSF.

Mission and Vision

The SCTO's primary objective is to catalyse valuable and innovative clinical research in Switzerland, aiming to make new and better therapies available to society. It serves as a central cooperation platform for patient-oriented clinical research, promoting efficiency, innovation, and visibility in the field.

Industry Significance

As a nationally significant research infrastructure, the SCTO plays a pivotal role in advancing clinical research in Switzerland. By harmonising processes, optimising best practices, and providing resources, it enhances the quality and efficiency of clinical studies, thereby contributing to the development of effective and safe therapies.

Key Strategic Focus

Core Objectives

Enhancing Clinical Research Quality: Improving the design, implementation, and monitoring of clinical trials to ensure high standards.

Promoting Innovation: Encouraging the development of novel therapeutic approaches through collaborative research.

Ensuring Transparency: Advocating for open data sharing and transparency in clinical research processes.

Areas of Specialisation

Clinical Trial Units (CTUs): Managing a network of CTUs across Swiss university and cantonal hospitals to support clinical research.

Clinical Research Platforms: Operating eight specialised platforms focusing on key areas such as safety, data management, and patient involvement.

Key Technologies Utilised

Clinical Trial Management Systems (CTMS): Implementing advanced CTMS to streamline trial processes.

Data Analytics Tools: Utilising sophisticated analytics for data monitoring and decision-making.

Primary Markets Targeted

Academic Institutions: Collaborating with universities and research centres to foster clinical research.

Healthcare Providers: Partnering with hospitals and clinics to facilitate patient recruitment and data collection.

Pharmaceutical and Biotech Companies: Engaging with industry partners for clinical trial execution and data analysis.

Financials and Funding

Funding History

The SCTO has been funded by the State Secretariat for Education, Research and Innovation (SERI) and the Swiss National Science Foundation (SNSF) since its establishment. In 2024, the SCTO secured renewed funding for the 2025–2028 period, ensuring continued support for its initiatives.

Utilisation of Capital

The allocated funds are utilised to:

Support Clinical Research Projects: Providing resources and infrastructure for conducting clinical trials.

Develop Tools and Resources: Creating platforms and materials to assist researchers in trial design and implementation.

Enhance Training Programs: Offering educational opportunities to clinical research staff to improve skills and knowledge.

Pipeline Development

As a coordinating body, the SCTO does not develop its own clinical pipeline but supports a wide range of clinical research projects across various therapeutic areas, including oncology, infectious diseases, cardiology, and neurology. In 2024, the SCTO's Clinical Trial Unit (CTU) Network was involved in over 2,000 clinical research projects, training more than 8,000 clinical research staff.

Technological Platform and Innovation

Proprietary Technologies

Clinical Trial Management Systems (CTMS): Utilising advanced CTMS to streamline trial processes.

Data Analytics Tools: Employing sophisticated analytics for data monitoring and decision-making.

Significant Scientific Methods

Patient and Public Involvement (PPI): Integrating PPI into clinical research to ensure studies are designed with patient needs in mind.

Data Harmonisation: Standardising data collection and reporting to enhance comparability across studies.

Leadership Team

Executive Profiles

Prof. Dr. med. Alessandro Ceschi, M.Sc.: Appointed President of the SCTO in May 2025, Prof. Ceschi is a board-certified clinical pharmacologist and toxicologist, and a specialist in general internal medicine. He serves as Chief of Medical Education and Research at the Ente Ospedaliero Cantonale (EOC) and is a professor at the Faculty of Biomedical Sciences at Università della Svizzera italiana (USI).

Victoria Sarraf: Managing Director of the SCTO, responsible for overseeing the organisation's operations and strategic initiatives.

Competitor Profile

Market Insights and Dynamics

The Swiss clinical trials market is characterised by a strong emphasis on quality and efficiency, with a growing focus on patient-centric research. The market is expanding, driven by increasing investments in healthcare and a robust pipeline of clinical studies across various therapeutic areas.

Competitor Analysis

Swiss Biobanking Platform (SBP): A national coordination platform for human and non-human biobanks, supporting clinical research through the provision of biological samples.

Swiss TPH Clinical Trials: Specialises in the design, implementation, management, and monitoring of Phase I to Phase IV clinical trials, focusing on poverty-related diseases.

CROss Alliance: A private Swiss Contract Research Organisation (CRO) offering clinical development and trial services for drugs, medical devices, and nutraceutical products.

Strategic Collaborations and Partnerships

The SCTO collaborates with various national and international partners, including:

European Clinical Research Infrastructure Network (ECRIN): As a full member, the SCTO contributes to European clinical research initiatives, enhancing access to multicentre studies and infrastructures.

Swiss Research Network of Clinical Pediatric Hubs (SwissPedNet): Supporting national paediatric hubs to advance clinical research in paediatric populations.

Operational Insights

The SCTO's strategic focus on harmonising clinical research processes and promoting transparency positions it as a leader in the Swiss clinical trials market. Its extensive network of CTUs and specialised platforms provides a comprehensive infrastructure for conducting high-quality clinical studies.

Strategic Opportunities and Future Directions

Looking ahead, the SCTO aims to:

Enhance Patient and Public Involvement (PPI): Integrate PPI more deeply into clinical research to ensure studies are designed with patient needs in mind.